Delta-Fly Pharma, Inc. (4598) Cash flow
Market cap
¥1.8B
P/E ratio
-1.6x
Delta-Fly Pharma develops cancer treatments using a unique "modular drug discovery" approach that builds new drugs from existing cancer-fighting compounds.
| 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Depreciation & amortization | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Cash from operations | 100 | -585 | -1,649 | -727 | -940 | -1,303 | -1,280 | -1,835 | -1,557 |
| Capital expenditures | - | -2 | -13 | -1 | - | -0 | -1 | -0 | - |
| Cash from investing | - | -4 | -13 | -1 | - | -0 | 0 | -0 | - |
| Repurchases of common stock | - | - | -0 | - | -0 | -0 | - | - | - |
| Repayments of term debt | -6 | -7 | -7 | -6 | - | - | - | - | - |
| Cash from financing | 293 | 3,317 | 100 | 875 | 120 | 883 | 1,853 | 757 | 1,364 |